570398-27-5

Basic information

• Product Name: 3-Morpholinone, 2-[hydroxy(1-propyl-1H-imidazol-4-yl)methyl]-4-[(4-methoxyphenyl)meth yl]-
• CAS NO: 570398-27-5
• Molecular Formula: C19H25N3O4
• Molecular Weight: 359.425
• Mol File: 570398-27-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-Morpholinone, 2-[hydroxy(1-propyl-1H-imidazol-4-yl)methyl]-4-[(4-methoxyphenyl)meth yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Morpholinone, 2-[hydroxy(1-propyl-1H-imidazol-4-yl)methyl]-4-[(4-methoxyphenyl)meth yl]-(570398-27-5)
• EPA Substance Registry System: 3-Morpholinone, 2-[hydroxy(1-propyl-1H-imidazol-4-yl)methyl]-4-[(4-methoxyphenyl)meth yl]-(570398-27-5)

Safety Data

• Hazardous Substances Data: 570398-27-5(Hazardous Substances Data)

Upstream product

• 570398-19-5 4-(p-methoxybenzyl)morpholin-3-one 
• 199192-04-6 1-n-Propyl-1H-imidazole-4-carboxaldehyde 

Downstream Products

• 570398-39-9 C₁₉H₂₃N₃O₃ 

Relevant articles and documents

Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor

A suitable inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) has the potential to be a novel treatment for thrombosis. The TAFIa inhibitor UK-396082 (1) was used as a starting point to seek more potent analogues. With knowledge of encouraging human pharmacokinetics and toleration for the clinical candidate (1), the programme continued to seek structure-activity relationships (SAR) that could positively impact on both potency and half-life, and therefore the projected dose of any future nominated clinical agent. A series of oxygenated analogues based on compound 1 were prepared to evaluate changes in pharmacology, selectivity and pharmacokinetics.